Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437.
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Haim N, Ben-Shahar M, et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988;24:533–538.
   PubMedGoogle Scholar
• Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963–977.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008;87:429–430.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011;77:221–240.
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277–283.
   PubMed Web of Science ®Google Scholar
• Campbell C, Sawka C, Franssen E, Berinstein NL. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. Leuk Lymphoma 1999;35:119–127.
   PubMed Web of Science ®Google Scholar
• Case DC, Jr., Desch CE, Kalman LA, et al. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma 2007;7:354–360.
   PubMedGoogle Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299–1309.
   PubMed Web of Science ®Google Scholar
• Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009;7:99–108.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389–397.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–633.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Rituxan [prescribing information]. So. San Francisco, CA: Genentech, Inc.; 08/2014.
   Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Non-Hodgkin's Lymphomas. Version 2. 2014. [Internet]. Available from: www.nccn.org
   Google Scholar
• Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56.
   PubMedGoogle Scholar
• Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol 1993;4:651–656.
   Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402–2409.
   PubMed Web of Science ®Google Scholar
• Picozzi VJ, Pohlman BL, Morrison VA, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 2001;15:1296–1306; discussion 1310–1291, 1314.
   PubMed Web of Science ®Google Scholar
• Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 2011;27:79–86.
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009;31:1069–1081.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) 2012;26:488–495.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187–3205.
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008;6:109–118.
   PubMedGoogle Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Lee S, Knox A, Zeng IS, et al. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer 2013;21:841–846.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Saleh M, Whittaker S, et al. Severe neutropenia and relative dose intensity among patients < 65 and >/ = 65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy. Support Care Cancer 2014;22:1833–1841.
   PubMed Web of Science ®Google Scholar
• Jolis L, Carabantes F, Pernas S, et al. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. Eur J Cancer Care (Engl) 2013;22:513–521.
   PubMed Web of Science ®Google Scholar
• Choi MR, Solid CA, Chia VM, et al. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer 2014;22:1619–1628.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology – Myeloid Growth Factors. Version 2. 2014. [Internet]. Available from: www.nccn.org
   Google Scholar